merck

Merck & Co says Keytruda shows better results than chemotherapy in Phase III trials for lung cancer

pharmafile | June 17, 2016 | News story | Medical Communications MSD, Merck & Co, drug trial, keytruda, lung cancer 

US drug major Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced non-small-cell lung cancer showed superiority to standard chemotherapy.  

Based on the results, an independent data monitoring committee recommended that the trial be stopped and that patients in the chemotherapy arm of the study have the opportunity to receive Keytruda.

Roger Perlmutter, president, Merck Research Laboratories, said: “We believe that the Keynote-024 results have the potential to change the therapeutic paradigm in first-line treatment of non-small-cell lung cancer. We look forward to sharing these data with the medical community and with regulatory authorities around the world.”

Advertisement

The study enrolled 305 patients with treatment-naïve advanced NSCLC and high levels of the PD-L1 protein, defined as a tumour proportion score of at least 50%.

Merck said the safety profile of Keytruda in the trial was consistent with that observed in previously reported studies in patients with advanced NSCLC.

Keytruda is already available in a number of indications, and is trialling it in other indications such as head and neck cancer. It also recently received its fourth breakthrough therapy designation from the FDA for the treatment of refractory classical Hodgkin lymphoma

Anjali Shukla

Related Content

HUTCHMED completes enrolment in phase 3 trial for lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …

Lung cancer cells

Graphene-based biosensor to support new lung cancer screening test

HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …

FDA approves diagnostic tool for MET-targeted lung cancer therapy

The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay …

The Gateway to Local Adoption Series

Latest content